Neurocrine Biosciences | Beneficio Operativo



Operating Profit Cambio Fecha
AbbVie USD 3.73B 5.22B 2025-03
Acadia Pharmaceuticals USD 153.5M 121.86M 2024-12
Agios Pharmaceuticals USD -106629000 18.41M 2025-03
ALKERMES USD 13.79M 148.9M 2025-03
Alnylam Pharmaceuticals USD 18.08M 123.24M 2025-03
Amgen USD 1.29B 1.02B 2025-03
Biogen USD 311.2M 130.2M 2025-03
BioMarin Pharmaceutical USD 223.89M 62.49M 2025-03
Cytokinetics USD -139040000 1.76M 2024-12
Dynavax Technologies USD -1632000 11.71M 2024-12
Exelixis USD 163.21M 27.13M 2025-01
Gilead Sciences USD 2.24B 215M 2025-03
Halozyme Therapeutics USD 175.5M 12.3M 2024-12
Incyte USD 205.17M 96.34M 2025-03
Ionis Pharmaceuticals USD -146000000 35.18M 2025-03
Neurocrine Biosciences USD 142M 41.8M 2024-12
Pfizer USD 3.67B 4.08B 2025-03
Prothena USD -64897000 1.62M 2024-12
Regeneron Pharmaceuticals USD 591.7M 398.5M 2025-03
Repligen USD 6.58M 43.08M 2025-03
Sarepta Therapeutics USD 161.68M 139.48M 2024-12
Teva Pharmaceutical Industries USD 455M 506M 2024-12
Ultragenyx Pharmaceutical USD -122278000 9.71M 2024-12
Vertex Pharmaceuticals USD 1.03B 90.3M 2024-12



Neurocrine Biosciences Beneficio Operativo - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.